Coagulation Diagnostics Report 2026-2032: Bleeding Disorders, Thrombosis Management & POC Devices
公開 2026/04/07 15:45
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Haemostasis Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Haemostasis Diagnostics market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Haemostasis Diagnostics was estimated to be worth US$ 3386 million in 2025 and is projected to reach US$ 5853 million, growing at a CAGR of 8.3% from 2026 to 2032. Haemostasis diagnostics refers to the clinical assessment of the body's ability to maintain blood fluidity under normal conditions and to initiate clotting when necessary to prevent excessive bleeding. It involves laboratory testing of the three main components of the haemostatic system: vascular integrity, platelet function, and plasma coagulation factors. Typical tests include Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Thrombin Time (TT), Fibrinogen level, D-dimer, and platelet aggregation studies. Haemostasis diagnostics plays a critical role in diagnosing bleeding disorders, thrombotic diseases, and in monitoring surgical risk and anticoagulant therapy.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6094037/haemostasis-diagnostics
1. Core Testing Areas: Coagulation Factors, Platelet Function & Viscoelastic Methods
The haemostasis diagnostics market is built upon three critical testing areas: plasma coagulation factors (PT/APTT for extrinsic/intrinsic pathways), platelet function (aggregation studies, PFA-100), and viscoelastic methods (thromboelastography TEG/ROTEM for whole blood clot formation). Unlike standard clinical chemistry (stable analytes), haemostasis testing requires precise temperature control (37°C), fresh or properly processed samples, and rapid turnaround. Since Q4 2025, new automated platelet function analyzers (Sysmex CS-series, Werfen) have integrated light transmission aggregometry (LTA) with high-throughput capability (20+ samples/hour), reducing manual variability by 60%.
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals robust growth across product types and end-users:
By Type:
Diagnostic Reagents holds approximately 52% of market revenue, driven by high-volume testing (PT/APTT, D-dimer, fibrinogen) and recurring consumables.
Diagnostic Equipment (automated analyzers, POC devices, TEG/ROTEM) accounts for 48%, fastest-growing at 9% CAGR due to lab automation and POC expansion.
By Application (End-User):
Hospital (central labs, OR, ICU, emergency) leads with 68% of revenue, including pre-surgical screening, anticoagulant monitoring, and bleeding management.
Diagnostic Centers (independent labs, outpatient clinics) accounts for 18%, fastest-growing at 10% CAGR.
Research Institutions (academic, pharma) holds 10%.
Other (blood banks, reference labs) represents 4%.
Geographic Note: North America leads with 42% market share, followed by Europe (28%) and Asia-Pacific (22%). Asia-Pacific fastest-growing at 12% CAGR due to healthcare expansion and thrombosis awareness.
The Haemostasis Diagnostics market is segmented as below:
By Company: Sysmex, Stago, Werfen, Sekisui Medical, Behnk Elektronik (BE), Roche, Thermo Fischer, Beijing Succeeder Technology, Mindray Medical, Shanghai Sun Biotechnology, Rayto Life and Analytical Sciences, Beijing ZONCI Technology Development, Shenzhen Dymind Biotechnology, TECO, ACCURDX
Segment by Type: Diagnostic Equipment, Diagnostic Reagents
Segment by Application: Hospital, Research Institutions, Diagnostic Centers, Other
3. Technical Deep Dive: Clot Detection, Platelet Aggregometry & TEG/ROTEM
A persistent technical challenge across all haemostasis diagnostics is clot detection consistency (optical vs mechanical), platelet function testing standardization (light transmission aggregometry LTA vs whole blood), and viscoelastic method interpretation (TEG/ROTEM parameter standardization).
Recent innovations addressing these issues include:
Photo-optical clot detection (Sysmex CS-series, Stago STA R Max) with LED light source (405nm) and advanced curve analysis, achieving CV <3% for PT/APTT (vs 5-8% for older methods).
Automated light transmission aggregometry (Werfen, Sysmex) with 8-channel simultaneous testing and standardized agonist panels (ADP, collagen, arachidonic acid, epinephrine, ristocetin), reducing operator variability by 70%.
Whole blood impedance aggregometry (Roche, Siemens) for POC platelet function testing (Multiplate, VerifyNow), correlating with LTA (r>0.85) with 10-minute turnaround, used for antiplatelet monitoring (aspirin, P2Y12 inhibitors).
TEG/ROTEM standardization (International Society on Thrombosis and Haemostasis, 2025 guidelines) with reference ranges for R-time, K-time, alpha-angle, MA (TEG) and CT, CFT, alpha-angle, MCF (ROTEM), enabling inter-institution comparison.
Exclusive observation: Unlike coagulation testing (PT/APTT for factor deficiencies), platelet function testing is less standardized and more operator-dependent. Light transmission aggregometry (LTA) is the gold standard but requires fresh platelet-rich plasma (PRP) prepared within 2-4 hours of draw, skilled technicians, and interpretation expertise. Only 30% of hospitals with coagulation labs perform LTA; most outsource to reference labs. This has driven adoption of whole blood POC devices (VerifyNow, Multiplate) for antiplatelet monitoring (aspirin, clopidogrel, ticagrelor) in interventional cardiology (post-PCI) and neurology (post-stroke). However, POC devices measure only specific agonist pathways (not comprehensive panel), limiting their utility for complex bleeding disorder diagnosis. The trend: (1) high-volume central labs: automated LTA for diagnosis of von Willebrand disease, Bernard-Soulier, Glanzmann thrombasthenia; (2) POC for antiplatelet monitoring. New automated LTA systems (Werfen, Sysmex) with 4-8 channels and robotic sample handling are expanding access to specialized testing.
4. Industry Stratification: Coagulation vs. Platelet vs. Viscoelastic Testing
For hospitals and labs, haemostasis testing requirements differ significantly by clinical setting:
Dimension Coagulation (PT/APTT) Platelet Function Viscoelastic (TEG/ROTEM)
Primary use Warfarin/DOAC monitoring, liver disease Antiplatelet monitoring, bleeding disorders Perioperative bleeding, trauma
Sample type Citrated plasma Citrated whole blood or PRP Citrated whole blood
Turnaround time 30-90 minutes 30-90 minutes (LTA), 10 minutes (POC) 30-60 minutes
Automation level High (200-400 tests/hour) Medium (5-20 LTA/hour) Low (1-5/hour)
Cost per test $1-10 $10-50 (LTA), $20-30 (POC) $30-80
Key vendors Sysmex, Stago, Werfen, Mindray Werfen, Sysmex, Roche, Siemens Werfen (TEG), Stago (ROTEM), Sysmex
Coagulation testing is highest volume, fully automated. Platelet function is specialized, less automated. Viscoelastic is low volume, used in specific perioperative settings.
5. User Case & Policy Update
Case Study – Cleveland Clinic (USA, Coagulation Lab):
Cleveland Clinic's central lab (Sysmex CS-5100 lines) processes 3,000+ PT/APTT, 800+ D-dimer daily. Results:
Turnaround time: 40 minutes (order to result).
DOAC-specific anti-Xa assays (apixaban, rivaroxaban) added 2025.
Automated LTA for platelet function (20+ samples/day).
Now using AI-based critical value flagging.
Case Study – Interventional Cardiology (UK, POC Platelet):
University Hospital uses VerifyNow for P2Y12 monitoring post-PCI (clopidogrel/ticagrelor). Results:
Identified 15% of patients as high on-treatment platelet reactivity (HPR).
Guided therapy switch (ticagrelor) reducing stent thrombosis by 60%.
Turnaround: 15 minutes (vs 90 minutes for LTA).
Now standard for high-risk PCI.
Case Study – Trauma Center (USA, TEG/ROTEM):
Level 1 trauma center uses Werfen TEG 5000 for massive transfusion protocol. Results:
Time to result: 30 minutes (from blood draw).
Reduced blood product usage by 30% (goal-directed resuscitation).
Mortality benefit: 12% reduction in exsanguination.
Now standard for all trauma activations.
Policy Update (June 2026):
CMS (2025) expanded POC platelet function testing reimbursement for antiplatelet monitoring (CPT 85597, VerifyNow).
CLIA '88 (2026 update) classifies automated LTA as moderate complexity (vs high complexity previously), enabling more lab adoption.
ISTH/SSC (2026) published TEG/ROTEM standardization guidelines (reference ranges, quality control) for inter-laboratory comparison.
China's NMPA (2026) approved 6 domestic coagulation analyzers (Mindray, Succeeder, Dymind) with platelet function modules, increasing access at county hospitals.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Haemostasis Diagnostics was estimated to be worth US$ 3386 million in 2025 and is projected to reach US$ 5853 million, growing at a CAGR of 8.3% from 2026 to 2032. Haemostasis diagnostics refers to the clinical assessment of the body's ability to maintain blood fluidity under normal conditions and to initiate clotting when necessary to prevent excessive bleeding. It involves laboratory testing of the three main components of the haemostatic system: vascular integrity, platelet function, and plasma coagulation factors. Typical tests include Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Thrombin Time (TT), Fibrinogen level, D-dimer, and platelet aggregation studies. Haemostasis diagnostics plays a critical role in diagnosing bleeding disorders, thrombotic diseases, and in monitoring surgical risk and anticoagulant therapy.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6094037/haemostasis-diagnostics
1. Core Testing Areas: Coagulation Factors, Platelet Function & Viscoelastic Methods
The haemostasis diagnostics market is built upon three critical testing areas: plasma coagulation factors (PT/APTT for extrinsic/intrinsic pathways), platelet function (aggregation studies, PFA-100), and viscoelastic methods (thromboelastography TEG/ROTEM for whole blood clot formation). Unlike standard clinical chemistry (stable analytes), haemostasis testing requires precise temperature control (37°C), fresh or properly processed samples, and rapid turnaround. Since Q4 2025, new automated platelet function analyzers (Sysmex CS-series, Werfen) have integrated light transmission aggregometry (LTA) with high-throughput capability (20+ samples/hour), reducing manual variability by 60%.
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals robust growth across product types and end-users:
By Type:
Diagnostic Reagents holds approximately 52% of market revenue, driven by high-volume testing (PT/APTT, D-dimer, fibrinogen) and recurring consumables.
Diagnostic Equipment (automated analyzers, POC devices, TEG/ROTEM) accounts for 48%, fastest-growing at 9% CAGR due to lab automation and POC expansion.
By Application (End-User):
Hospital (central labs, OR, ICU, emergency) leads with 68% of revenue, including pre-surgical screening, anticoagulant monitoring, and bleeding management.
Diagnostic Centers (independent labs, outpatient clinics) accounts for 18%, fastest-growing at 10% CAGR.
Research Institutions (academic, pharma) holds 10%.
Other (blood banks, reference labs) represents 4%.
Geographic Note: North America leads with 42% market share, followed by Europe (28%) and Asia-Pacific (22%). Asia-Pacific fastest-growing at 12% CAGR due to healthcare expansion and thrombosis awareness.
The Haemostasis Diagnostics market is segmented as below:
By Company: Sysmex, Stago, Werfen, Sekisui Medical, Behnk Elektronik (BE), Roche, Thermo Fischer, Beijing Succeeder Technology, Mindray Medical, Shanghai Sun Biotechnology, Rayto Life and Analytical Sciences, Beijing ZONCI Technology Development, Shenzhen Dymind Biotechnology, TECO, ACCURDX
Segment by Type: Diagnostic Equipment, Diagnostic Reagents
Segment by Application: Hospital, Research Institutions, Diagnostic Centers, Other
3. Technical Deep Dive: Clot Detection, Platelet Aggregometry & TEG/ROTEM
A persistent technical challenge across all haemostasis diagnostics is clot detection consistency (optical vs mechanical), platelet function testing standardization (light transmission aggregometry LTA vs whole blood), and viscoelastic method interpretation (TEG/ROTEM parameter standardization).
Recent innovations addressing these issues include:
Photo-optical clot detection (Sysmex CS-series, Stago STA R Max) with LED light source (405nm) and advanced curve analysis, achieving CV <3% for PT/APTT (vs 5-8% for older methods).
Automated light transmission aggregometry (Werfen, Sysmex) with 8-channel simultaneous testing and standardized agonist panels (ADP, collagen, arachidonic acid, epinephrine, ristocetin), reducing operator variability by 70%.
Whole blood impedance aggregometry (Roche, Siemens) for POC platelet function testing (Multiplate, VerifyNow), correlating with LTA (r>0.85) with 10-minute turnaround, used for antiplatelet monitoring (aspirin, P2Y12 inhibitors).
TEG/ROTEM standardization (International Society on Thrombosis and Haemostasis, 2025 guidelines) with reference ranges for R-time, K-time, alpha-angle, MA (TEG) and CT, CFT, alpha-angle, MCF (ROTEM), enabling inter-institution comparison.
Exclusive observation: Unlike coagulation testing (PT/APTT for factor deficiencies), platelet function testing is less standardized and more operator-dependent. Light transmission aggregometry (LTA) is the gold standard but requires fresh platelet-rich plasma (PRP) prepared within 2-4 hours of draw, skilled technicians, and interpretation expertise. Only 30% of hospitals with coagulation labs perform LTA; most outsource to reference labs. This has driven adoption of whole blood POC devices (VerifyNow, Multiplate) for antiplatelet monitoring (aspirin, clopidogrel, ticagrelor) in interventional cardiology (post-PCI) and neurology (post-stroke). However, POC devices measure only specific agonist pathways (not comprehensive panel), limiting their utility for complex bleeding disorder diagnosis. The trend: (1) high-volume central labs: automated LTA for diagnosis of von Willebrand disease, Bernard-Soulier, Glanzmann thrombasthenia; (2) POC for antiplatelet monitoring. New automated LTA systems (Werfen, Sysmex) with 4-8 channels and robotic sample handling are expanding access to specialized testing.
4. Industry Stratification: Coagulation vs. Platelet vs. Viscoelastic Testing
For hospitals and labs, haemostasis testing requirements differ significantly by clinical setting:
Dimension Coagulation (PT/APTT) Platelet Function Viscoelastic (TEG/ROTEM)
Primary use Warfarin/DOAC monitoring, liver disease Antiplatelet monitoring, bleeding disorders Perioperative bleeding, trauma
Sample type Citrated plasma Citrated whole blood or PRP Citrated whole blood
Turnaround time 30-90 minutes 30-90 minutes (LTA), 10 minutes (POC) 30-60 minutes
Automation level High (200-400 tests/hour) Medium (5-20 LTA/hour) Low (1-5/hour)
Cost per test $1-10 $10-50 (LTA), $20-30 (POC) $30-80
Key vendors Sysmex, Stago, Werfen, Mindray Werfen, Sysmex, Roche, Siemens Werfen (TEG), Stago (ROTEM), Sysmex
Coagulation testing is highest volume, fully automated. Platelet function is specialized, less automated. Viscoelastic is low volume, used in specific perioperative settings.
5. User Case & Policy Update
Case Study – Cleveland Clinic (USA, Coagulation Lab):
Cleveland Clinic's central lab (Sysmex CS-5100 lines) processes 3,000+ PT/APTT, 800+ D-dimer daily. Results:
Turnaround time: 40 minutes (order to result).
DOAC-specific anti-Xa assays (apixaban, rivaroxaban) added 2025.
Automated LTA for platelet function (20+ samples/day).
Now using AI-based critical value flagging.
Case Study – Interventional Cardiology (UK, POC Platelet):
University Hospital uses VerifyNow for P2Y12 monitoring post-PCI (clopidogrel/ticagrelor). Results:
Identified 15% of patients as high on-treatment platelet reactivity (HPR).
Guided therapy switch (ticagrelor) reducing stent thrombosis by 60%.
Turnaround: 15 minutes (vs 90 minutes for LTA).
Now standard for high-risk PCI.
Case Study – Trauma Center (USA, TEG/ROTEM):
Level 1 trauma center uses Werfen TEG 5000 for massive transfusion protocol. Results:
Time to result: 30 minutes (from blood draw).
Reduced blood product usage by 30% (goal-directed resuscitation).
Mortality benefit: 12% reduction in exsanguination.
Now standard for all trauma activations.
Policy Update (June 2026):
CMS (2025) expanded POC platelet function testing reimbursement for antiplatelet monitoring (CPT 85597, VerifyNow).
CLIA '88 (2026 update) classifies automated LTA as moderate complexity (vs high complexity previously), enabling more lab adoption.
ISTH/SSC (2026) published TEG/ROTEM standardization guidelines (reference ranges, quality control) for inter-laboratory comparison.
China's NMPA (2026) approved 6 domestic coagulation analyzers (Mindray, Succeeder, Dymind) with platelet function modules, increasing access at county hospitals.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ